Skip to content
S7110Senate2023-2024 SessionSame asA10107

Stop PBM Underpayments to Pharmacies

Official title

“Relates to reimbursements practices of pharmacy benefit managers”

Sponsor James SkoufisSD-42Affects Health
Status
In Senate Committee
Health
Impact
7/10
Significant
Passage
0%

Bill progress

Step 2 of 7

In committee · Health

What's happening

This bill requires pharmacy benefit managers to reimburse independent pharmacies at least as much as they reimburse their own affiliates and sets new rules for appeals on drug pricing.

Why it matters

  1. Levels the playing field for independent pharmacies by requiring pharmacy benefit managers (PBMs) to reimburse them at rates no lower than those paid to PBM-owned or affiliated pharmacies, which could help sustain local businesses and maintain access to community-based care.

  2. Establishes clearer and fairer procedures for pharmacies to appeal drug pricing decisions, including a mechanism to adjust reimbursement if a drug cannot be obtained at or below the set price, potentially reducing financial losses for independent pharmacies.

  3. Limits PBM ability to use non-transparent or preferential pricing methodologies for their own affiliates, promoting greater transparency in prescription drug pricing and potentially curbing anti-competitive practices.

  4. Could lead to more stable pharmacy networks and improved patient access, especially in rural or underserved areas where independent pharmacies are often the only providers.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Pharmacies and pharmacists

    The bill would require reimbursement at least equal to what PBM affiliates receive for the same services and allow affected claims to be reversed and rebilled when specified acquisition-cost challenges require a pricing adjustment.

  • Pharmacy benefit managers

    PBMs denying reimbursement appeals would have to identify an equivalent drug available through the pharmacy’s primary wholesaler and raise their pricing benchmark above acquisition cost if the specified condition is met.

  • PBM-affiliated pharmacies

    Their reimbursement rates would serve as the floor for payments to other pharmacies, calculated per unit using the same generic product identifier or generic code number.

Headline styles

Stop PBM Underpayments to Pharmacies

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
James Skoufis

Senator · Senate District 42

Chair, Investigations And Government Operations

No co-sponsors yet.

History

  1. Referred to health
  2. Referred to health

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A10107Assembly

Stop PBM Underpaying Pharmacies

In Assembly Committee · Health · Sponsor Anna Kelles

Impact 7 · Significant0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

7110

2023-2024 Regular Sessions

IN SENATE

May 18, 2023

Introduced by Sen. SKOUFIS -- read twice and ordered printed, and when printed to be committed to the Committee on Health

AN ACT to amend the public health law, in relation to reimbursement rates of pharmacy benefit managers

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Paragraph (e) of subdivision 4 of section 280-a of the public health law, as added by chapter 828 of the laws of 2021, is amended and a new subdivision 4-a is added to read as follows:

(e) (i) if an appeal is denied, the pharmacy benefit manager shall identify the national drug code of a therapeutically equivalent drug, as determined by the federal Food and Drug Administration, that is available for purchase by pharmacies in this state from wholesalers registered pursuant to subdivision four of section sixty-eight hundred eight of the education law that the pharmacist or pharmacy purchases the majority of prescription drugs for resale from at a price which is equal to or less than the maximum allowable cost or other reimbursement pricing methodology used by the pharmacy benefits manager to determine cost for that drug as determined by the pharmacy benefit manager.

(ii) if the national drug code number provided by the pharmacy benefit manager is not available below the pharmacy acquisition cost from the pharmaceutical wholesaler from whom the pharmacy or pharmacist purchases the majority of prescription drugs for resale, then the pharmacy benefit manager shall adjust the maximum allowable cost or other pricing methodology used by the pharmacy benefits manager to determine cost above the challenging pharmacy's pharmacy acquisition cost and permit the pharmacy to reverse and rebill each claim affected by the inability to procure the drug at a cost that is equal to or less than the previously challenged maximum allowable cost.

4-a. Reimbursement. (a) A pharmacy benefit manager shall not reimburse a pharmacy or pharmacist in this state an amount less than the amount

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD05319-02-3

that the pharmacy benefit manager reimburses a pharmacy benefit manager affiliate for providing the same pharmacist services.

(b) The amount shall be calculated on a per unit basis based on the same generic product identified or generic code number.

§ 2. This act shall take effect on the ninetieth day after it shall have become a law.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the public health law, in relation to reimbursement rates of pharmacy benefit managers

Purpose

To require pharmacy benefit managers (PBMs) in New York State to provide information about therapeutically equivalent drugs and adjust reimburse- ment rates if the drugs are not available at a cost equal to or less than the maximum allowable cost.

Summary of provisions

Section 1: Amends paragraph (e) of subdivision 4 of section 280-a of the public health law. A new subdivision 4-a is added and states that if an appeal is denied, the pharmacy benefit manager must identify a therapeu- tically equivalent drug, as determined by the FDA, that is available for purchase by pharmacies in the state at a price equal to or less than the maximum allowable cost determined by the pharmacy benefit manager.

Read the full memo (641 words)

Subdivision 4(e)(ii) states that if the identified drug is not available below the pharmacy acquisition cost, the pharmacy benefit manager must adjust the maximum allowable cost and allow the pharmacy to reverse and rebill affected claims.

Subdivision 4-a(a) states that a pharmacy benefit manager must reimburse a pharmacy or pharmacist in the state an amount that is not less than what the pharmacy benefit manager reimburses its affiliate for providing the same pharmacist services.

Subdivision 4-a(b) clarifies that the reimbursement amount should be calculated on a per unit basis based on the same generic product identi- fied or generic code number.

Section 2: Sets effective date.

Justification

In the 1960s, insurance companies began to expand their coverage of prescription medications. This expansion of coverage led to increased caseloads that put .a significant administrative burden on the insurance industry. Prescription drug coverage plans began to outsource the proc- essing and administration of claims to new companies called Pharmacy Benefit Managers (PBMS). As the price of prescription medications increased, PBMs were able to wield their significant power within the prescription drug pricing industry and act as a "middleman," negotiating discounts and rebates with a manufacturer in exchange for a preferable position on an insurance company's drug formulary. The savings from these rebates and discounts are meant to pass through to patients making drugs more affordable.

PBMS negotiate rebates with the drug's manufacturer in exchange for a favorable position on an insurance company's formulary. A favorable position on a formulary makes it more affordable to consumers thus increasing the drug's market share. Despite the fact that many PBMs claim to pass on the savings from these rebates to the consumer, many PBMs hold on to large portions or all of these rebates as profit.

PBMs also act on behalf of the insurance company to reimburse pharmacies for the cost of purchasing the medication from the distributor and dispensing the medication to the consumer. These costs, and often a small profit, are covered through the "administrative fee" charged to insurance companies they are contracted with.

Oftentimes, PBMs will also markup - sometimes dramatically - the differ- ence between the amount they reimburse the pharmacy and the amount they charge their clients. These controversial practices, called "spread pricing," "claw backs," or "chargebacks," are most common with generic drugs, which make up almost 901 of all prescriptions dispensed in the United States, and where most believe PBMs make their greatest profit.

This bill will address concerns regarding the practices of pharmacy benefit managers (PBMs) and their impact on pharmacies and pharmacists in New York State. By requiring PBMs to provide information about thera- peutically equivalent drugs and adjust reimbursement rates when drugs are not available at fair prices, the bill seeks to promote transparen- cy, protect pharmacies from financial burdens, and ensure access to affordable medications for patients.

Prior legislative history

New bill.

Fiscal implications

TBD.

Effective date

This act shall take effect on the ninetieth day after it shall have become a law.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.